Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Novo Nordisk partners OpenAI on R&D “transformation”

 April 14, 2026

Pharmaphorum

Seeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.

M&A / DealsRead full story

Post navigation

Travere Therapeutics gains FDA approval for sparsentan in FSGS →
← Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com